Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2
Science · 13.11.2025 · 390 (6774) · 702-709
DOI: 10.1126/science.adv2684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 13.11.2025. Verfasst von Joseph E Klebba und 41 weiteren Autor:innen. Beteiligte Einrichtung: Vividion Therapeutics, 5820 Nancy Ridge Drive, San Diego, CA, USA. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, ras Proteins, Neoplasms, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK, Wellcome Trust, NIGMS NIH HHS.
Abstract (Originalsprache)
Genetic disruption of the RAS binding domain (RBD) of phosphoinositide 3-kinase alpha (PI3Kα) impairs the growth of tumors driven by the small guanosine triphosphatase RAS in mice and does not affect PI3Kα’s role in insulin-mediated control of glucose homeostasis. Selectively blocking the RAS-PI3Kα interaction may represent a strategy for treating RAS-dependent cancers as it avoids the toxicity associated with inhibitors of PI3Kα lipid kinase activity. We developed compounds that bind covalently to cysteine 242 in the RBD of PI3K p110α and block RAS activation of PI3Kα activity. In mice, inhibitors slow the growth of RAS mutant tumors and human epidermal growth factor receptor 2–overexpressing tumors, particularly when combined with other inhibitors of the RAS/mitogen-activated protein kinase pathway, without causing hyperglycemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vividion Therapeutics, 5820 Nancy Ridge Drive, San Diego, CA, USA.
- Francis Crick Institute, 1 Midland Road, London, UK.
ORCID-Profile: Joseph E Klebba, Steffen M Bernard, Stephanie Grabow, Junko Tamiya, Cynthia Berry, Antonio Esparza-Oros, Richard Lin, Marie Pariollaud, Holly Parker, Sareena Rana, Erick Aitichson, Karl Bedke, Jacyln C Brannon, Benjamin D Horning, Mohamed Ismail, Kelsey N Lamb, Justine Lu, John J Sigler, Mona Tomaschko, Miriam Molina-Arcas, Brian N Cook, David S Weinstein, Julian Downward, Matthew P Patricelli
Förderung
- Cancer Research UK
- Wellcome Trust
- NIGMS NIH HHS
- U.S. Department of Energy
- University of Kentucky
- Wellcome
- H2020 European Research Council
- Medical Research Council Canada
Zitieren
APA
Klebba, J. E., Roy, N., Bernard, S. M., Grabow, S., Hoffman, M. A., Miao, H., Tamiya, J., Wang, J., Berry, C., Esparza-Oros, A., Lin, R., Liu, Y., Pariollaud, M., Parker, H., Mochalkin, I., Rana, S., Snead, A. N., Walton, E. J., Wyrick, T. E., …, & Patricelli, M. P. (2025). Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2. Science, 390(6774), 702-709. https://doi.org/10.1126/science.adv2684
Vancouver
Klebba JE, Roy N, Bernard SM, Grabow S, Hoffman MA, Miao H, et al. Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2. Science. 2025;390(6774):702-709. doi:10.1126/science.adv2684
BibTeX
@article{Klebba2025,
author = {Klebba, Joseph E and Roy, Nilotpal and Bernard, Steffen M and Grabow, Stephanie and Hoffman, Melissa A and Miao, Hui and Tamiya, Junko and Wang, Jinwei and Berry, Cynthia and Esparza-Oros, Antonio and Lin, Richard and Liu, Yongsheng and Pariollaud, Marie and Parker, Holly and Mochalkin, Igor and Rana, Sareena and Snead, Aaron N and Walton, Eric J and Wyrick, Taylor E and Aitichson, Erick and Bedke, Karl and Brannon, Jacyln C and Chick, Joel M and Hee, Kenneth and Horning, Benjamin D and Ismail, Mohamed and Lamb, Kelsey N and Lin, Wei and Lu, Justine and Pastuszka, Martha K and Pollock, Jonathan and Sigler, John J and Tomaschko, Mona and Tran, Eileen and Yue, Chanyu and Kinsella, Todd M and Molina-Arcas, Miriam and Cook, Brian N and Simon, Gabriel M and Weinstein, David S and Downward, Julian and Patricelli, Matthew P},
title = {Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2},
journal = {Science},
year = {2025},
volume = {390},
number = {6774},
pages = {702--709},
doi = {10.1126/science.adv2684}
}
EUVIMED